删除或更新信息,请邮件至freekaoyan#163.com(#换成@)

中山大学肿瘤防治中心导师教师师资介绍简介-朱孝峰

本站小编 Free考研考试/2021-05-15

朱孝峰 职务:华南肿瘤学国家重点实验室副主任
职称:研究员,博士生导师
专长:肿瘤信号转导、自噬调控与靶向药物研究

主要简介 详细介绍 预约挂号

  朱孝峰,男,1970年9月出生,博士, 教授,博士生导师。中山大学肿瘤防治中心华南肿瘤学国家重点实验室副主任,主要从事肿瘤信号转导、自噬调控与靶向药物研究。
  2000年在美国乔治城大学癌症中心学习,2002年获中国药理学会施维雅青年药理学工作者奖,2007年入选教育部新世纪优秀人才支持计划,现为广东省抗癌协会抗肿瘤药物专业委员会候任主任委员,广东省肿瘤药理专业委员会主任委员,Chin J Cancer、Front Pharmacol、Advances in Therapy等杂志编委。
  先后承担国家自然科学基金重点项目1项,面上项目7项、973计划课题(组长)1项、973计划课题(骨干)1项以及863计划、省市科技项目等多项课题,发表高水平收录论文90余篇,以通讯作者发表高水平收录论文40余篇包括Nature Communications, Leukemia, Autophagy, Oncogene(4篇)等国际著名杂志,主编人民卫生出版社出版的《信号转导与疾病》和广东科技出版社出版《肿瘤生物治疗学》等专著,申请新药发明专利九项,其中五项已获授权,研发的抗肿瘤新药阿诺宁注射液已转让企业开发。



  朱孝峰,男,1970年9月出生,博士, 教授,博士生导师。中山大学肿瘤防治中心华南肿瘤学国家重点实验室副主任,主要从事肿瘤信号转导、自噬调控与靶向药物研究。2000年在美国乔治城大学癌症中心学习,2002年获中国药理学会施维雅青年药理学工作者奖,2007年入选教育部新世纪优秀人才支持计划,现为广东省抗癌协会抗肿瘤药物专业委员会候任主任委员,广东省肿瘤药理专业委员会主任委员,中国抗癌协会抗癌药物专业委员会委员,中国药理学会肿瘤药理及化疗专业委员会委员,Chin J Cancer、Front Pharmacol、Advances in Therapy等杂志编委。先后承担国家自然科学基金重点项目1项,面上项目7项、973计划课题(组长)1项、973计划课题(骨干)1项以及863计划、省市科技项目等多项课题,发表高水平收录论文90余篇,以通讯作者发表高水平收录论文40余篇包括Nature Communications, Leukemia, Autophagy, Oncogene(4篇)等国际著名杂志,主编人民卫生出版社出版的《信号转导与疾病》和广东科技出版社出版《肿瘤生物治疗学》等专著,申请新药发明专利九项,其中五项已获授权,研发的抗肿瘤新药阿诺宁注射液已转让企业开发。

近年以通讯作者发表的主要论文:

  1.Ting Sun, Xuan Li, Peng Zhang, Wen-Dan Chen, Hai-Liang Zhang, Dan-Dan Li, Rong Deng, Xiao-Jun Qian, Lin Jiao, Jiao Ji, Yuan-Tian Li, Rui-Yan Wu, Yan Yu, Gong-Kan Feng, Xiao-Feng Zhu*. Acetylation of Beclin 1 inhibits autophagosome maturation and promotes tumour growth. Nat Commun. 2015; 6: 7215.
  2.Jing-Hong Chen, Peng Zhang, Wen-Dan Chen, Dan-Dan Li, Rong Deng, Xuan Li, Jiao Ji, Gong-Kan Feng, Yi-Xin Zeng, Jian-Wei Jiang, Xiao-Feng Zhu*. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to topotecan in cancer cells. Autophagy, 2015; 11(2): 239-52
  3.Xu XL, Cheng H, Tang MS, Zhang HL, Wu RY, Yu Y, Li X, Wang XM, Mai J, Yang CL, Jiao L, Li ZL, Zhong ZM, Deng R, Li JD, Zhu XF*. A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer. Oncotarget, 2016 Dec 22. doi: 10.18632/oncotarget.14100. [Epub ahead of print]
  4.Huang L, Lan WJ, Deng R, Feng GK, Xu QY, Hu ZY, Zhu XF*, Li HJ. Additional New Cytotoxic Triquinane-Type Sesquiterpenoids Chondrosterins K-M from the Marine Fungus Chondrostereum sp. Mar Drugs, 2016;14(9). pii: E157.
  5.Jiao L, Li DD, Yang CL, Peng RQ, Guo YQ, Zhang XS, Zhu XF*. Reactive oxygen species mediate oxaliplatin-induced epithelial-mesenchymal transition and invasive potential in colon cancer. Tumour Biol. 2016;37(6):8413-23.
  6.Lu QP, Chen WD, Peng JR, Xu YD, Cai Q, Feng GK, Ding K, Zhu XF*, Guan Z. Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells. Oncol Lett, 2016;12(5):3598-3608.
  7.Xiao-jun Qian, Yun-tian Li, Yan Yu, Yang Fen, Rong Deng, Jiao Ji, Lin Jiao, Xuan Li, Rui-Yan Wu, Wen-Dan Chen, Gong-Kan Feng, Xiao-Feng Zhu*. Inhibition of DNA Methyltransferase as a Novel Therapeutic Strategy to Overcome Acquired Resistance to Dual PI3K/mTOR Inhibitors. Oncotarget. 2015; 6(7): 5134-46
  8.Juan Qin, Jiao Ji, Rong Deng, Jun Tang, Fen Yang, Gong-Kan Feng, Wen-Dan Chen, Xiao-Qi Wu, Xiao-Jun Qian, Shao-Hua Chang, Ke Ding, Xiao-Feng Zhu*. DC120, a novel AKT inhibitor, preferentially inhibits nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2 expression. Oncotarget. 2015; 6(9):6944-58
  9.Yun-Tian Li, Xiao-Jun Qian, Yan Yu, Zhen-Hua Li, Rui-Yan Wu, Jiao Ji, Lin Jiao, Xuan Li, Peng-Fei Kong, Wen-Dan Chen, Gong-Kan Feng, Rong Deng, Xiao-Feng Zhu*. EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy. Oncotarget. 2015 Apr 29. [Epub ahead of print]
  10.Yang F, Deng R, Qian XJ, Chang SH, Wu XQ, Qin J, Feng GK, Ding K, Zhu XF*. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer. Cell Death Dis. 2014;5:e1114.
  11.He JH, Liao XL, Wang W, Li DD, Chen WD, Deng R, Yang D, Han ZP, Jiang JW, Zhu XF*. Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy. Int J Oncol, 2014:45(3): 1099-108.
  12.Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF*. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. PLoS One. 2013;8(3):e59879
  13.Xiao-Yue Zhang, Xiao-Qi Wu, Rong Deng, Ting Sun, Gong-Kan Feng, Xiao-Feng Zhu*. Upregulation of sestrin 2 expression via JNK pathway activation contributes to autophagy induction in cancer cells. Cell Signal. 2013 Jan;25(1):150-8
  14.Rong Deng, Fen Yang, Shao-Hua Chang, Jun Tang, Juan Qin, Gong-Kan Feng, Ke Ding, Xiao-Feng Zhu*. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth. Mol Pharmacol, 2012, 82(2):189-98
  15.Jun Tang, Rong Deng, Rong-Zhen Luo, Guo-Ping Shen, Mo-Yan Cai, Zi-Ming Du, Shang Jiang, Ming-Tian Yang, Jian-Hua Fu, Xiao-Feng Zhu*. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat, 2012, 134(2):549-60
  16.Dan-Dan Li, Ting Sun, Xiao-Qi Wu, Shu-Peng Chen, Rong Deng, Shan Jiang, Gong-Kan Feng, Jin-Xuan Pan, Xiao-shi Zhang, Yi-Xin Zeng, Xiao-Feng Zhu*. The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment. PLoS ONE*, 2012, 7(9): e45058. doi:10.1371/journal.pone.**
  17.Fen Yang, Wen-Dan Chen, Rong Deng, Dan-Dan Li, Ke-Wei Wu, Gong-Kan Feng, Hou-Jin Li, Xiao-Feng Zhu*. Hirsutanol A induces apoptosis and autophagy via reactive oxygen species accumulation in breast cancer MCF-7 cells. J Pharmacol Sci, 2012, 119(3):214-20
  18.Wei Qin, Zhen-Mei Lin, Deng R, Dan-Dan Li, Zhi Song, Yi-Guo Tian, RF Wang, JQ Ling, Xiao-Feng Zhu*. p38a MAPK is involved in BMP-2-induced odontoblastic differentiation of human dental pulp cells. Int Endod J, 2012,45(3):224-33
  19.Ning-Ning Zhou, Jun Tang, Wen-Dan Chen, Gong-Kan Feng, Bin-Fen Xie, Zong-Chao Liu, Dajun Yang, Xiao-Feng Zhu*. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells. Life Sci, 2012, 22;90(19-20):770-5
  20.Ting Sun, Dan-Dan Li, Lin-Lin Wang, Liang-Ping Xia, Jian-Guo Ma, Zhong Guan, Gong-Kan Feng, Xiao-Feng Zhu*. c-Jun NH2-terminal kinase activation is essential for up-regulation of LC3 during ceramide induced autophagy in human nasopharyngeal carcinoma cells. J Trans Med, 2011, 9:161
  21.Shan Jiang, Yong Li, Ying-Hui Zhu, Xiao-Qi Wu, Jun Tang, Zheng Li, Gong-Kan Feng, Rong Deng, Dan-Dan Li, Rong-Zhen Luo, Mei-Fang Zhang, Wei Qin, Xin Wang, Wei-Hua Jia, Xiao-Feng Zhu*. Intensive expression of UNC-51-like kinase 1 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Science, 2011, 102: 1568–1575
  22.Rong Deng, Jun Tang, Jian-Guo Ma, Shu-Peng Chen, Liang-Ping Xia, Wen-Jun Zhou, Dan-Dan Li, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene, 2011, 30: 944-55
  23.Dan-Dan Li, Jin-Feng Guo, Jia-Jia Huang, Lin-Lin Wang, Rong Deng, Jian-Nan Liu, Gong-Kan Feng, Ding-Jun Xiao, Song-Zhi Deng, Xiao-Shi Zhang, Xiao-Feng Zhu*. Rhabdastrellic acid-A induced autophagy-associated cell death through blocking Akt pathway in human cancer cells. PLos One, 2010, 5(8):e12176
  24.Rong Deng, Jun Tang, Bin-Fen Xie, Gong-Kan Feng, Yue-Han Huang, Zong-Chao Liu, Xiao-Feng Zhu*. SYUNZ-16, a new synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of AKT/FOXO signal pathway. Int J Cancer, 2010, 127(1):220-9
  25.Wen-Jun Zhou, Rong Deng, Xiao-Yue Zhang, Gong-Kan Feng, Lian-Quan Gu, Xiao-Feng Zhu*. G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells. Mol Cancer Ther, 2009, 8:3203-3213
  26.Dan-Dan Li, Lin-Lin Wang, Rong Deng, Jun Tang, Yang Shen, Jin-Feng Guo, Yao Wang, Liang-Ping Xia, Gong-Kan Feng, Quentin Q Liu, Wen-Lin Huang, Yi-Xin Zeng, Xiao-Feng Zhu*. The pivotal role of c-Jun-NH2-terminal kinase-mediated Beclin-1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene, 2009, 28, 886-898.
  27.Rong Deng, Jun Tang, Liang-Ping Xia, Dan-Dan Li, Lin-Lin Wang, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. ExcisaninA induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. Mol Cancer Ther, 2009, 8(4): 873-882.
  28.Dan-Dan Li, Xiao-Qi Wu, Ju Tang, Xiao-Yi Wei, Xiao-Feng Zhu*. ON-III inhibits erbB-2 tyrosine kinase receptor signal pathway and triggers apoptosis through induction of Bim in breast cancer cells. Cancer Biol & Ther, 2009; 8(8):739-43
  29.Yuan XW, Zhu XF*, Liang SG, Fan Q, Chen ZX, Huang XF, Sheng PY, He AS, Yang ZB, Deng R, Feng GK, Liao WM. Interferonalpha enhances etoposide-induced apoptosis in human osteosarcoma U2OS cells by a p53-dependent pathway. Life Sci, 2008, 82(7-8): 393-401
  30.Guo JF, Zhou JM, Zhang Y, Deng R, Liu JN, Feng GK, Liu ZC, Xiao DJ, Deng SZ, Zhu XF*. Rhabdastrellic acid-A inhibited PI3K/Akt pathway and induced apoptosis in human leukemia HL-60 cells. Cell Biol Int. 2008, 32(1):48-54
  31.Xiang-Wei Yuan, Xiao-Feng Zhu*, Wei-Ming Liao. p14ARF sensitizes human osteosar- coma cells to cisplatin-induced apoptosis in a p53-independent manner. Cancer Biology & Therapy, 2007, 6(7): 1074 -1080
  32.Xiang-Wei Yuan, Xiao-Feng Zhu*, Huang XF, Sheng PY, He AS, Yang ZB, Deng R, Feng GK, Liao WM. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis1. Acta Pharmacol Sin, 2007, 28(11):1835-41.
  33.Yu-Ping Mei, Jun-Min Zhou, Yi Wang, He Huang, Rong Deng, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle, 2007, 6(11): 1379-1385.
  34.Jian-nan Liu, Rong Deng, Jin-Feng Guo, Jun-Min Zhou, Gong-Kan Feng, Zhi-Shu Huang, Lian-Quan Gu, Yi-Xin Zeng, Xiao-Feng Zhu*. Inhibition of myc promoter and telomerase activity and induction of delayed apoptosis by SYUIQ-5, a novel G-quadruplex interactive agent in leukemia cells. Leukemia, 2007, 21(6), 1300-1302
  35.Zhi-Yi Cheng, Wen-Jie Li, Feng He, Jun-Min Zhou and Xiao-Feng Zhu*. Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem, 2007, 15(3): 1533-1538
  36.Rong Deng, Wenming Li, Zhong Guan, Jun-Min Zhou, Yi Wang, Yu-Ping Mei, Ming-Tao Li, Gong-Kan Feng, Wenlin Huang, Zong-Chao Liu, Yifan Han, Yi-Xin Zeng and Xiao-Feng Zhu*. Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis. Oncogene, 2006, 25(53):7070-7
  37.Jun-Min Zhou, Xiao-Feng Zhu*, Yu-Jin Lu, Rong Deng, Zhi-Shu Huang, Yu-Ping Mei, Yi Wang, Wenlin Huang, Zong-Chao Liu, Lian-Quan Gu and Yin-Xin Zeng. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene, 2006, 25, 503-511
  38.Yu-Ping Mei, Xiao-Feng Zhu*, Jun-Min Zhou, He Huang, Rong Deng, Yi-Xin Zeng. siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression. Cancer Letters, 2006, 232, 189-198
  39.Jin-Jun Zhu, Fu-Bo Li, Xiao-Feng Zhu*, Wei-Ming Liao. The p33(ING1b) tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells. Life Sciences, 2006, 78(13):1469-77
  40.Jin-Jun Zhu, Fu-Bo Li, Jun-Min Zhou, Zong-Chao Liu, Xiao-Feng Zhu*, Wei-Ming Liao. The Tumor Suppressor p33(ING1b) Enhances Taxol-induced Apoptosis by p53-Dependent Pathway in Human Osteosarcoma U2OS Cells. Cancer Biol Ther, 2005, 4(1):39-47.
  41.Zong-Wei Wang, Jun-Min Zhou, Zhi-Shu Huang, Ai-Ping Yang, Zong-Chao Liu, Yun-Fei Xia, Yi-Xin Zeng, Xiao-Feng Zhu*. Aloe polysaccharides mediated radioprotective effect through the inhibition of apoptosis. J Radiat Res, 2004, 45 (3): 447-454.
主编的专著
  1) 《信号转导与疾病》,2012年5月人民卫生出版社出版,(黄文林,朱孝峰主编)
  2) 《肿瘤生物治疗学》,2005,12,广东科技出版社,(姜文奇,张晓实,朱孝峰,李志铭主编)
  3) 《肿瘤分子靶向治疗》,2009,5,人民卫生出版社,(朱孝峰,副主编)
  4) 《黑色素瘤基础与临床》,2010,11,人民卫生出版社,(朱孝峰,副主编)
  5) 《肿瘤360》,2014,10,凤凰科学技术出版社,(朱孝峰,副主编)
申请的专利
  1.5-噻唑酰胺类化合物及生物学应用,2010.10,中国,ZL55。
  2.一种抗肿瘤化合物Chondrosterin J 及其制备方法与运用, 2013.12 , 中国,3.4。
  3.Hirsutanols A 在制备抗肿瘤药物中的应用,2009.10,中国,ZL1.0。
  4.紫草萘醌类衍生物及其在制备抗癌药物中的应用。中国专利号:ZL**.9
  5.脂肪氨基取代喹啉衍生物及其制备方法和制药用途。中国专利号:ZL7.3;国际专利申请号:PCT/CN2004/000175。
  6.Houttuyninum compositions and methods for inhibiting the activity of erbB-2 based thereon. 国际专利申请号:PCT/US01/43123。
  7.碘化-3,3’-二乙基-9-甲基-硫杂羰花青的抗肿瘤新用途。中国专利申请号:**.6。
  8.人表皮生长因子受体2酪氨酸激酶抑制剂。 中国专利申请号:6.3
  9.一种查尔酮肟及其组合物、制备方法和应用。中国专利号:ZL7.6
    更新时间:2017.2.13






相关话题/肿瘤 中山大学

  • 领限时大额优惠券,享本站正版考研考试资料!
    大额优惠券
    优惠券领取后72小时内有效,10万种最新考研考试考证类电子打印资料任你选。涵盖全国500余所院校考研专业课、200多种职业资格考试、1100多种经典教材,产品类型包含电子书、题库、全套资料以及视频,无论您是考研复习、考证刷题,还是考前冲刺等,不同类型的产品可满足您学习上的不同需求。 ...
    本站小编 Free壹佰分学习网 2022-09-19
  • 中山大学肿瘤防治中心导师教师师资介绍简介-贾卫华
    贾卫华职务:华南肿瘤学国家重点实验室PI,肿瘤资源库负责人职称:博士、教授、博士生导师专长:肿瘤分子流行病学主要简介详细介绍预约挂号  2014年中国青年女科学家获得者、科技部中青年创新领军人才入选者,广东省珠江********,2013年国家自然科学基金****科学基金获得者(流行病学)。研究领域 ...
    本站小编 Free考研考试 2021-05-15
  • 中山大学肿瘤防治中心导师教师师资介绍简介-康铁邦
    康铁邦职务:中山大学肿瘤防治中心实验研究部副主任,华南肿瘤学国家重点实验室PI职称:博士、研究员、博士生导师,国家****科学基金获得者专长:肿瘤新靶标的调控与干预、细胞囊泡与肿瘤耐药和肿瘤转移等主要简介详细介绍预约挂号姓名:康铁邦职称:博士、教授、博士生导师,国家****科学基金获得者职务:中山大 ...
    本站小编 Free考研考试 2021-05-15
  • 中山大学肿瘤防治中心导师教师师资介绍简介-关新元
    关新元职务:中山大学“****”人才引进****职称:教授、博士生导师专长:研究兴趣集中于寻找与肝癌、食道癌及鼻咽癌发生相关的基因、肿瘤干细胞和肿瘤微环境。主要简介详细介绍预约挂号 关新元教授于1993年获得美国亚利桑那大学(UniversityofArizona)遗传学博士,在美国密西根大学(Un ...
    本站小编 Free考研考试 2021-05-15
  • 中山大学肿瘤防治中心导师教师师资介绍简介-刘强
    刘强职务:肿瘤分子靶向治疗实验室主任职称:教授,博士生导师专长:肿瘤生物标记物及靶向药物筛选、肿瘤干细胞及分化治疗、肿瘤微环境及免疫治疗、肿瘤转移及三维培养主要简介详细介绍预约挂号973首席科学家(肿瘤干细胞),国家****基金获得者(肿瘤学/分子靶向治疗),教育部外籍专家(美籍),中山大学**** ...
    本站小编 Free考研考试 2021-05-15
  • 中山大学肿瘤防治中心导师教师师资介绍简介-王辉云
    王辉云职务:肿瘤生物组学与标志物课题组组长职称:研究员,博士生导师专长:肿瘤发病机制、肿瘤遗传与表观遗传、肿瘤标志物与治疗主要简介详细介绍预约挂号  王辉云,医学博士,中山大学****引进人才、教授、博士生导师,现任华南肿瘤学国家重点实验室肿瘤生物组学与标志物课题组组长。1982年衡阳医学院医疗专业 ...
    本站小编 Free考研考试 2021-05-15
  • 中山大学肿瘤防治中心导师教师师资介绍简介-宋立兵
    宋立兵职务:华南肿瘤学国家重点实验室PI职称:研究员,博士生导师专长:恶性肿瘤的发病机制和早期诊断主要简介详细介绍预约挂号研究方向:1.恶性肿瘤侵袭转移分子机制     2.肿瘤标志物和早期诊断     3.肿瘤分子分型和基因治疗  2001年获得中山医科大学医学博士学位。2002-2004年先后在 ...
    本站小编 Free考研考试 2021-05-15
  • 中山大学肿瘤防治中心导师教师师资介绍简介-高嵩
    高嵩职务:华南肿瘤学国家重点实验室结构生物学研究室PI职称:研究员、博士生导师专长:生物大分子结构解析,蛋白质科学主要简介详细介绍预约挂号1983年7月出生学科:1)结构生物学,2)生物化学与分子生物学专业特长:生物大分子结构解析,蛋白质科学研究方向:1.dynamin家族成员的结构和功能研究2.人 ...
    本站小编 Free考研考试 2021-05-15
  • 中山大学肿瘤防治中心导师教师师资介绍简介-邓务国
    邓务国职务:中山大学“****”引进人才职称:教授、博士生导师专长:主要简介详细介绍预约挂号男,博士,教授,博士生导师,中山大学“****”引进人才,现受聘于中山大学肿瘤防治中心华南肿瘤学国家重点实验室。1997年在北京大学获得理学博士学位(专业:生物化学和应用化学)。博士期间,主要从事黄酮类天然药 ...
    本站小编 Free考研考试 2021-05-15
  • 中山大学肿瘤防治中心导师教师师资介绍简介-刘然义
    刘然义职务:职称:教授(研究员)博士生导师专长:恶性肿瘤的靶向治疗研究主要简介详细介绍预约挂号  1989年毕业于南京大学生物化学系(本科),1998年获得同济医科大学生物化学与分子生物学专业硕士学位,2007年获得中山大学肿瘤学博士学位。现任中山大学肿瘤防治中心、华南肿瘤学国家重点实验室研究员、教 ...
    本站小编 Free考研考试 2021-05-15
  • 中山大学肿瘤防治中心导师教师师资介绍简介-贝锦新
    贝锦新职务:华南肿瘤学国家重点实验室PI,中山大学精准医学中心实验平台负责人...职称:研究员、博士生导师;专长:复杂疾病遗传学和基因组学研究主要简介详细介绍预约挂号贝锦新,男,38岁,研究员、博士生导师;华南肿瘤学国家重点实验室PI,中山大学精准医学中心实验平台负责人。中山大学"****"引进人才 ...
    本站小编 Free考研考试 2021-05-15